logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Amgen Inc drugs

    FiltersReset Filters
    21 results

    • aimovig

      (erenumab-aooe)
      Amgen Inc
      Usage: AIMOVIG is indicated for the preventive treatment of migraines in adults.

    • amjevita

      (adalimumab-atto)
      Amgen Inc
      Usage: AMJEVITA is indicated for treating various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients, depending on the specific condition.

    • aranesp - darbepoetin alfa injection, solution

      (Darbepoetin Alfa)
      Amgen Inc

    • avsola

      (infliximab-axxq)
      Amgen Inc
      Usage: AVSOLA is indicated for reducing signs and symptoms, inducing and maintaining remission in moderately to severely active Crohn's disease (adult and pediatric), ulcerative colitis (adult and pediatric), and other conditions like rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis.

    • bkemv

      (eculizumab-aeeb)
      Amgen Inc
      Usage: BKEMV is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AchR) antibody positive. It is not for Shiga toxin E. coli related HUS.

    • blincyto

      (blinatumomab)
      Amgen Inc
      Usage: BLINCYTO is indicated for treating CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adults and pediatric patients (≥1 month) during first or second remission with minimal residual disease (MRD ≥0.1%), as well as in cases of relapsed or refractory ALL and during the consolidation phase of chemotherapy.

    • corlanor

      (ivabradine)
      Amgen Inc
      Usage: Corlanor is indicated to reduce hospitalization risk for adults with stable, symptomatic chronic heart failure (left ventricular ejection fraction ≤ 35%) and resting heart rate ≥ 70 bpm. It is also used for pediatric patients aged 6 months and older with stable symptomatic heart failure due to dilated cardiomyopathy.

    • evenity

      (romosozumab-aqqg)
      Amgen Inc
      Usage: EVENITY is indicated for the treatment of osteoporosis in postmenopausal women at high fracture risk, including those with a history of fractures or multiple risk factors, or those intolerant to other therapies. Limitation: use is restricted to 12 monthly doses due to waning effectiveness.

    • imdelltra

      (Tarlatamab-dlle)
      Amgen Inc
      Usage: IMDELLTRA is indicated for treating adult patients with extensive stage small cell lung cancer (ES-SCLC) who have disease progression after platinum-based chemotherapy. Its approval is based on overall response rate and duration, with continued approval dependent on confirming clinical benefit in further studies.

    • imlygic

      (talimogene laherparepvec)
      Amgen Inc
      Usage: IMLYGIC is indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in melanoma patients with recurrence after surgery. It does not improve overall survival or affect visceral metastases.